revmaxx Voice AIVoice AI
Acoustic Respiratory AI — Research Programme

Building India's first zero-infrastructure acoustic AI screening model for respiratory disease.

Peer-reviewed literature confirms that cough acoustics carry clinically significant information about respiratory disease. Every attempt to deploy this at scale has failed, not because the science is wrong, but because models trained on clean, controlled audio degrade in real-world conditions. Our approach: train where we deploy, from real OPDs, under real acoustic conditions.

Validated

End-to-end pipeline: ingestion, quality gating and feature extraction

1,218

Recordings — PoC dataset

25,000+

Target — full study

The Scientific Gap We Are Closing

Every published acoustic respiratory AI study was built on controlled-environment recordings with limited geographic and demographic diversity. None have been validated under real Indian OPD conditions, ambient noise, diverse patient populations, varying disease severity, that define actual clinical deployment environments.

None cover the full spectrum of respiratory disease with molecularly and objectively confirmed diagnosis labels. None have been trained on the real-world compressed audio that a low-bandwidth deployment channel actually produces. This dataset does not exist. We are building it.

What Makes This Study Different

  • Domain-Matched Training

    We are training on real-world compressed audio from real OPDs, the same acoustic domain as deployment. Previous models trained on clean audio collapsed in production; this is the gap our data collection is specifically designed to close.

  • Confirmed Diagnosis Labels

    Two-phase protocol separates recording from labelling. Ground truth uses GeneXpert for TB, spirometry for COPD and asthma, radiology for ILD. No provisional impressions.

  • Multi-Disease Classification

    TB, COPD, Asthma, Bronchitis, ILD, Pleural Disease, classified simultaneously. Real OPD clinical reality, not binary TB-vs-healthy models.

  • Longitudinal Trajectory Data

    Repeat recordings from the same patients across their treatment journey. No published acoustic respiratory AI dataset has this. Enables treatment monitoring, a new research frontier.

  • Geographic Diversity at Scale

    Multi-site recruitment across urban, semi-urban and rural India. Systematic demographic characterisation including occupation, city of residence and environmental exposure.

  • Zero Infrastructure Deployment

    Once validated, this model reaches every Indian with a respiratory concern through a single voice message, no app download, no clinic visit, no new infrastructure.

  • Methodological Rigour — Sub-Cohort Separation

    Recordings linked to clinically diagnosed (non-molecularly confirmed) outcomes are retained in a separate sub-cohort and excluded from primary model training. These are used only for post-hoc validation, ensuring the primary model trains exclusively on confirmed-diagnosis ground truth. No prior acoustic AI study has made this distinction explicitly.

Study Design

A prospective multi-centre observational study collecting cough recordings linked to confirmed clinical diagnoses across participating chest and pulmonary medicine outpatient departments in India. No intervention. No drugs. No disruption to clinical workflow.

  • Prospective · Multi-Centre · Observational
  • 25,000+ Target Recordings
  • Two-Phase Confirmed Diagnosis Protocol
  • ICMR / CDSCO Compliant
  • Three-Tier Hybrid Consent Framework

Research Outputs — In Order of Impact

  1. 1

    A Deployable Screening Model

    A validated, zero-infrastructure acoustic respiratory AI screening model, deployable immediately to 500 million Indians without app download, without infrastructure, without clinical staff. No such model exists today.

  2. 2

    India's First Confirmed-Diagnosis Acoustic Dataset

    A structured, multi-geography acoustic repository supporting peer-reviewed clinical validation and post-hoc academic analyses across participating institutional sub-cohorts.

  3. 3

    A Published Collection Methodology

    A peer-reviewed methodology for low-bandwidth-domain acoustic data collection establishing the standard for future studies globally, including the dual-track longitudinal protocol.

  4. 4

    A Treatment Monitoring Signal

    Longitudinal acoustic trajectory data across treatment journeys, enabling a treatment monitoring model for TB and COPD that could supplement expensive spirometry and GeneXpert follow-up in resource-limited settings.

What Participating Institutions Gain

  • Named co-authorship for the Respiratory Medicine team on publications targeting leading international peer-reviewed journals in respiratory medicine and AI
  • Institutional recognition as a contributing research site in all publications, presentations and policy submissions, among a select group of leading hospitals across India
  • Priority deployment of the validated acoustic screening model before public commercialisation, built partly on your own patient data
  • Non-commercial use of the validated screening model by your Respiratory Medicine team, once available
  • Full de-identified sub-cohort data access for MD and DNB Pulmonary Medicine resident thesis dissertations, enabling postgraduate research output from your own patient data
  • All coordinator salary, PPE, IEC fees and infrastructure costs funded entirely by RespiC AI, nothing falls on the participating institution

Where We Are Today — October 2026

  • Proof of concept validated: end-to-end acoustic ingestion, quality gating and feature extraction pipeline verified across 1,218 retrospective recordings. Tested across multiple device types (iPhone, Android). Architecture confirmed deployment-ready.
  • Legal counsel engaged: DPDP 2023 compliance, IEC documentation, MoU framework.
  • CTRI registration in preparation. DPIIT Startup India registered.

Research Collaboration Enquiries

We are actively onboarding clinical research sites across India. If your institution is interested in participating as a co-investigator site, we would welcome a conversation.

  • Soumyadip Ghosal
  • Founder & CEO, RespiC AI
  • soumyadip@revmaxx.online
  • +91 8910363003